Dicot Receives Grant from Vinnova, Sweden"s Agency for Innovation, to Strengthen Intellectual Property Portfolio
Press release: Uppsala, June 18, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that the company has received a grant of SEK 100,000 from Vinnova"s program "IP-checks Q2 2019" for Intellectual Property Review by Dicot AB.
Vinnova is a government agency with the goal to aid Swedish companies to remain leading global players in research and innovation. Vinnova"s IP-check program is part of the effort to strengthen the companies" awareness and knowledge of intellectual property rights and to help build strong IP portfolios.
Dicot, with a process for managing intellectual property rights in place, will use the grant to carry out an intellectual property rights review with the assistance of an established patent agency, in order to further sharpen intellectual property rights processes.
"We are pleased to accept the contribution from Vinnova as this enables us to strengthen our IP portfolio which provides greater value for our stakeholders," commented Göran Beijer, CEO of Dicot.
For more information, please contact:
Julie Silber
CFO/Investor Relations Director, Dicot
Tel.: +46-79-3486277
Email: [email protected]
This is information that DICOT is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.40 (CET) on July 18, 2019.
About Dicot AB:
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, LibiguinTM, for the treatment of sexual dysfunctions and is in preclinical. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se
Filer
Om Dicot Pharma
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
